Has Alan Schatzberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $219,423 in general payments to Alan Schatzberg, MD across 106 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Schatzberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Schatzberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Schatzberg, MD

Psychiatry · Stanford, CANPI 1518093129

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $189,871 of the $219,423 with a category attached, or 86.5%. Sage Therapeutics, LLC accounts for 78.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $68,492 and has fallen 68.8% since, to $21,401 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$219,423in general payments, 2019–2025

Across 106 payments — averaging $2070.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sage Therapeutics, LLC$171K
Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
Tris Pharma Inc$10K
Boehringer Ingelheim International GmbH$8K
Janssen Scientific Affairs, LLC$6K
Sunovion Pharmaceuticals Inc.$6K
plus $7K from 5 others

$14,887in research payments, 2019–2025

Across 6 payments — averaging $2481.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$9K
Neuronetics, Inc.$4K
Boehringer Ingelheim International GmbH$2K

What the payments were for

Consulting fees$189,87187%
Speaking & faculty fees$15,4047%
Travel & lodging$10,6365%
Food & beverage$3,5122%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sage Therapeutics, LLC	58	$171,310
Otsuka Pharmaceutical Development & Commercialization, Inc.	9	$11,573
Tris Pharma Inc	4	$9,500
Boehringer Ingelheim International GmbH	7	$7,900
Janssen Scientific Affairs, LLC	11	$5,971
Sunovion Pharmaceuticals Inc.	1	$5,904
Jazz Pharmaceuticals Inc.	8	$3,509
Janssen Research & Development, LLC	2	$1,612
Otsuka America Pharmaceutical, Inc.	3	$1,296
Pfizer	1	$700
Grifols, S.A.	2	$147

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SUNOSI$3,330
Dyanavel XR$2,500
Zurzuvae$2,447
ZULRESSO$1,393
CELEBREX$700

How this compares

$219,423 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024

$9,183

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lurasidone Hcl	12	$18,519
Divalproex Sodium	12	$643
Mirtazapine	12	$602
Olanzapine	15	$582
Pramipexole DihydrochloridePramipexole Di-Hcl	13	$450
Bupropion Hcl SrBupropion Hcl	12	$358
Venlafaxine Hcl ErVenlafaxine Hcl	16	$225
Bupropion XlBupropion Hcl	11	$156

Paid to pharmacies, not to this prescriber.

Other psychiatry in Stanford

Bibi DasStanford$1.4M
Maurice OhayonStanford$113K
Gustavo AlvaOrange$5.8M
John KooSan Francisco$3M
Jason KelloggIrvine$2.7M
Jonathan MeyerSan Diego$2.3M
Charles Tuan-Tu NguyenIrvine$2.1M
Manoj WaikarLos Gatos$1.9M
Gerald MaguireSan Juan Capistraco$1.8M
Salima BrillmanSunnyvale$1.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →